Research brief · 2026-09-09
Does Resistance Training Protect Muscle During GLP-1 Weight Loss?
Semaglutide, tirzepatide and liraglutide are prescription medications, and a recurring concern is that some of the weight they take off is lean mass rather than fat. The obvious follow-up question is whether resistance training changes that. The honest answer is that the evidence is suggestive but incomplete, and the trial built to settle it has not reported yet.
The closest completed trial is S-LITE, published by Lundgren and colleagues in the New England Journal of Medicine in 2021. In Copenhagen, 195 adults with obesity first lost about 13 kilograms on an eight-week low-calorie diet. They were then randomised to a year of supervised exercise, daily liraglutide, both combined, or placebo. All three active strategies beat placebo on weight, but the body-composition result is the relevant one: the combination group's body-fat percentage fell 3.9 points, compared with 1.7 in the exercise-only group and 1.9 in the liraglutide-only group. A 2024 follow-up by Jensen and colleagues in EClinicalMedicine tracked 109 participants for a year after all treatment stopped. Regain was six kilograms larger after stopping liraglutide alone than after stopping exercise alone, and people who had exercised were far more likely to still be down at least ten percent.
The catch is that S-LITE tested a general moderate-to-vigorous exercise programme, not resistance training as its own arm. A 2026 meta-analysis by Eisa and Barood in Diabetes, Obesity and Metabolism pooled 20 randomised trials with 15,782 participants and found lean mass made up 35.2 percent of weight lost on semaglutide, 25.4 percent on tirzepatide and 26.8 percent on liraglutide, not meaningfully different from lifestyle-only weight loss at 26.2 percent. Lifestyle programmes that included resistance training stood apart at 17.5 percent. But that group never took a GLP-1 drug; it is a comparison across separate trials, not a randomised test of adding lifting to the medication.
A case series by Tinsley and Nadolsky in 2025 described three people who combined resistance training with higher protein intake on semaglutide or tirzepatide; two of them gained lean soft tissue while losing substantial weight. Three people demonstrate that the outcome is possible, not that it is typical.
The gap is now being addressed directly. The LEAN-PREP trial, whose protocol was published in BMJ Open in 2026, is enrolling 232 adults starting semaglutide or tirzepatide and randomising them to control, resistance exercise, protein supplementation or both, with MRI-measured thigh muscle as the primary outcome. Until it reports, the claim that lifting protects muscle on these drugs is a reasonable inference from general exercise research, not a tested result. Whether preserved lean mass means preserved strength has not been measured either. Exercise and medication plans belong with a physician.
Sources
- Lundgren JR, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined (S-LITE)
- New England Journal of Medicine 2021
- Jensen SBK, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment
- EClinicalMedicine 2024
- Eisa N, Barood O. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
- Diabetes, Obesity & Metabolism 2026
- Alawadhi AA, et al. LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): protocol for a randomised controlled trial
- BMJ Open 2026
Peptide Proof reports what studies found. We do not give medical advice, dosing guidance, or treatment recommendations.